Skye Bioscience, Inc. Proceeds from Sale of Productive Assets
Skye Bioscience, Inc. (SKYE) reported Proceeds from Sale of Productive Assets of $1.22 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2024-11-07
- Skye Bioscience, Inc. proceeds from sale of productive assets for the quarter ending 2024-09-30 was $72.84K.
- Skye Bioscience, Inc. proceeds from sale of productive assets for the quarter ending 2024-06-30 was $0.00.
- Skye Bioscience, Inc. proceeds from sale of productive assets for the quarter ending 2024-03-31 was $1.15M, a 79.30% decline year-over-year.
- Skye Bioscience, Inc. proceeds from sale of productive assets for the quarter ending 2023-09-30 was $0.00.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month |
|---|---|---|---|
| 2024-09-30 | $72.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $72.84K derived: sum of 2 quarters · filed 2024-11-07 | $1.22M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.15M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $1.15M 10-Q · filed 2024-05-10 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $5.53M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $5.53M 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $5.53M 10-Q · filed 2024-05-10 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |